May 4 (Reuters) - Abcellera Biologics Inc ABCL.O :
* NEW ABCELLERA-DISCOVERED ANTIBODY THAT NEUTRALIZES VIRAL VARIANTS OF COVID-19, LY-COV1404, ENTERS CLINICAL TRIALS
* ABCELLERA BIOLOGICS INC - NEW PRECLINICAL DATA SHOW THAT LY-COV1404 BINDS AND NEUTRALIZES ALL CURRENTLY KNOWN CIRCULATING SARS-COV-2 VARIANTS OF CONCERN
* ABCELLERA BIOLOGICS INC - LY-COV1404 BINDS TO A RARELY MUTATED REGION OF SARS-COV-2 SPIKE PROTEIN, SUGGESTING EFFECTIVENESS AGAINST EMERGING VARIANTS
* ABCELLERA BIOLOGICS INC - LY-COV1404 NEUTRALIZES AUTHENTIC SARS-COV-2 WITH HIGH POTENCY IN VITRO
* ABCELLERA BIOLOGICS INC - LY-COV1404 ENTERS CLINICAL TRIALS AS PART OF LILLY'S BLAZE-4 STUDY IN PATIENTS WITH MILD-TO-MODERATE COVID-19 ILLNESS